Summary
FTRE Chart
FTRE vs. ILMN: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?
Fortrea Holdings Inc. (FTRE) Q1 2025 Earnings Call Transcript
Fortrea Holdings Inc. (NASDAQ:FTRE ) Q1 2025 Earnings Conference Call May 12, 2025 9:00 AM ET Company Participants Hima Inguva - Head, Investor Relations and Corporate Development Tom Pike - Chief Executive Officer Jill McConnell - Chief Financial Officer Peter Neupert - Chairman and Interim CEO Conference Call Participants David Windley - Jefferies Justin Bowers - DB Patrick Donnelly - Citi Eric Coldwell - Baird Elizabeth Anderson - Evercore Charles Rhyee - TD Cowen Luke Sergott - Barclays Matt Sykes - Goldman Sachs Max Smock - William Blair Michael Ryskin - Bank of America Operator Ladies and gentlemen, thank you for standing by. And welcome to Fortrea First Quarter 2025 Earnings Conference Call.
Fortrea Holdings Inc. (FTRE) Q1 Earnings and Revenues Beat Estimates
Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.07 per share. This compares to loss of $0.04 per share a year ago.
Fortrea Holdings Inc. Dividends
Fortrea Holdings Inc. Earnings
| 18 Aug 2025 (In 1 month) Date | | 0.44 Cons. EPS | - EPS |
| 11 Aug 2025 (In 3 weeks) Date | | 0.06 Cons. EPS | - EPS |
| 12 May 2025 Date | | - Cons. EPS | 0.02 EPS |
| 10 Mar 2025 Date | | 0.37 Cons. EPS | 0.18 EPS |
| 11 Nov 2024 Date | | 0.25 Cons. EPS | 0.23 EPS |
| 18 Aug 2025 (In 1 month) Date | | 0.44 Cons. EPS | - EPS |
| 11 Aug 2025 (In 3 weeks) Date | | 0.06 Cons. EPS | - EPS |
| 12 May 2025 Date | | - Cons. EPS | 0.02 EPS |
| 10 Mar 2025 Date | | 0.37 Cons. EPS | 0.18 EPS |
| 11 Nov 2024 Date | | 0.25 Cons. EPS | 0.23 EPS |
Fortrea Holdings Inc. (FTRE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Fortrea Holdings Inc. ever had a stock split?
Fortrea Holdings Inc. Profile
| Biotechnology Industry | Healthcare Sector | Peter M. Neupert CEO | NASDAQ (NGS) Exchange | 34965K107 Cusip |
| US Country | 15,000 Employees | - Last Dividend | - Last Split | 3 Jul 2023 IPO Date |
Overview
Fortrea Holdings Inc. is a distinguished contract research organization that has carved a niche for itself in the provision of comprehensive development services for biopharmaceutical products and medical devices on a global scale. Established in 2023 and based in Durham, North Carolina, Fortrea Holdings Inc. distinguishes itself through its specialized operation in two core segments: Clinical Services and Enabling Services. This structured approach allows the company to cater to a wide array of needs within the biopharmaceutical and medical device development space, offering its services to pharmaceutical, biotechnology, and medical device organizations. Through its inception, Fortrea Holdings Inc. has been dedicated to advancing the field of clinical development by leveraging its expertise and innovative technologies to simplify and optimize processes for its clients worldwide.
Products and Services
- Clinical Services:
- Enabling Services:
- Delivery Models:
- Technology Enabled Trial Solutions:
- Post-Approval Services and Consulting:
Fortrea's Clinical Services segment offers comprehensive support across the clinical pharmacology and clinical development spectrum. This includes a full range of services from early phase clinical development strategies to phase I-IV clinical trial management. By focusing on efficient and effective clinical trial execution, Fortrea ensures that its clients can advance through the development pipeline with confidence and precision.
The Enabling Services segment is designed to streamline the clinical trial process through patient access and clinical trial technology solutions. This includes sophisticated tools for complex randomization and optimized trial drug supply processes, making clinical trials more efficient and effective. Through these services, Fortrea aims to reduce the logistical hurdles associated with clinical trials, thereby speeding up the development timeline and reducing costs for its clients.
Understanding the varied needs of its clients, Fortrea offers multiple delivery models including full-service, functional service provider (FSP), and hybrid structures. This flexibility allows clients to choose the model that best fits their project requirements, resources, and goals, ensuring a tailored approach to clinical trial management and development services.
Fortrea is at the forefront of integrating technology into the clinical trial process. The company provides differentiated technology-enabled solutions that facilitate every phase of clinical trials, from planning and recruitment to data collection and analysis. These innovative solutions enable higher efficiency, accuracy, and accessibility for clinical trials, propelling the industry forward and setting new standards for trial management.
Even after approval, Fortrea supports its clients with a suite of post-approval services and consulting expertise. This ensures that transitioning from development to market is as smooth and efficient as possible, offering continued support in terms of market analysis, regulatory compliance, and post-marketing studies. Furthermore, Fortrea's consulting services provide valuable insights and strategies for overcoming the unique challenges faced by biopharmaceutical and medical device companies.
Contact Information
